The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; none of the 20 sources its claims cite is checked for support yet.
Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes
Abstract
Context: Low testosterone levels are common in men with type 2 diabetes and may be associated with insulin resistance. Objective: We investigated prevalence of testosterone deficiency and the relationship between testosterone and insulin resistance in a large cohort of men with type 2 and type 1 diabetes. Design: The study was a cross-sectional survey of 580 men with type 2 diabetes and 69 men with type 1 diabetes. A subgroup of 262 men with type 2 diabetes was then reassessed after a median of 6 months. Results: Forty-three percent of men with type 2 diabetes had a reduced total testosterone, and 57% had a reduced calculated free testosterone. Only 7% of men with type 1 diabetes had low total testosterone. By contrast, 20.3% of men with type 1 diabetes had low calculated free testosterone, similar to that observed in type 2 diabetes (age-body mass index adjusted odds ratio = 1.4; 95% confidence interval = 0.7–2.9). Low testosterone levels were independently associated with insulin resistance in men with type 1 diabetes as well as type 2 diabetes. Serial measurements also revealed an inverse relationship between changes in testosterone levels and insulin resistance. Conclusions: Testosterone deficiency is common in men with diabetes, regardless of the type. Testosterone levels are partly influenced by insulin resistance, which may represent an important avenue for intervention, whereas the utility of testosterone replacement remains to be established in prospective trials.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a single-center cross-sectional survey, testosterone deficiency was common in men with diabetes: 43% of men with type 2 diabetes had low total testosterone and 57% had low calculated free testosterone, while 20.3% of men with type 1 diabetes had low calculated free testosterone. Low testosterone indices were independently associated with insulin resistance in both diabetes types, and longitudinal changes in testosterone were inversely related to changes in insulin resistance in a type 2 diabetes subgroup.
Key findings
- Among men with type 2 diabetes, 43% had low total testosterone (<10 nmol/L) and 57% had low calculated free testosterone (<0.23 nmol/L); among men with type 1 diabetes, 7% had low total testosterone but 20.3% had low calculated free testosterone, similar to age- and BMI-adjusted men with type 2 diabetes (adjusted odds ratio 1.4; 95% CI 0.7–2.9).
- Low total testosterone in type 2 diabetes was independently associated with insulin resistance by HOMA-IR (odds ratio 1.2; 95% CI 1.0–1.4), and calculated free testosterone was independently associated with insulin sensitivity in type 2 diabetes (partial correlation coefficient −0.10; P = 0.02) and with eGDR in type 1 diabetes (P = 0.04).
- In 262 men with type 2 diabetes reassessed after a median of 6 months, the change in total testosterone was inversely related to the change in HOMA-IR (P = 0.01), and the change in calculated free testosterone was inversely correlated with the change in HOMA-IR (P = 0.03).
- The prevalence of low calculated free testosterone approximately doubled per decade of age in type 2 diabetes (adjusted odds ratio 2.0; 95% CI 1.4–2.4) and in type 1 diabetes (adjusted odds ratio 2.4; 95% CI 1.4–3.9).
Methods
- Cross-sectional survey of 580 men with type 2 diabetes and 69 men with type 1 diabetes at a single clinic; 6 men with type 2 diabetes were excluded from statistical analysis, and a randomly selected subgroup of 262 men with type 2 diabetes was reassessed after a median of 6 months (range 1–15 months).
- Fasting blood samples were drawn between 0800 and 1000 h; total testosterone was measured by Access assay, SHBG by Immulite, and calculated free testosterone was derived using Vermeulen’s formula. Low total testosterone was defined as <10 nmol/L and low calculated free testosterone as <0.23 nmol/L.
- Insulin resistance was estimated by HOMA-IR in type 2 diabetes and by eGDR in type 1 diabetes; analyses used logistic regression, multiple regression, ANOVA, analysis of covariance, and nonparametric tests as appropriate.
Limitations
- The paper states that it did not obtain a detailed symptomatology history, so the biochemical testosterone deficiency may not represent a true hypogonadal state; it also states that a single low testosterone level is inadequate for diagnosing hypogonadism because of variability, and on repeat testing 27% of men with low total testosterone and 33% with low calculated free testosterone had normal levels.
- The paper states that longitudinal changes in testosterone in type 1 diabetes remain to be explored and that the utility of testosterone replacement remains to be established in prospective trials.
- Evident from the text: the study was observational and single-center, with a tertiary referral cohort that had longstanding diabetes and high complication prevalence, which may limit generalizability and cannot establish causality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
29 Own result · 14 Not checked yet · 7 Own interpretation · 5 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only 7% of men with type 1 diabetes had low total testosterone.”
- Also stated in: § Prevalence of testosterone deficiency in men with type 1 diabetes · plain
“Few men with type 1 diabetes had low TT (7.2%, P Ͻ 0.001, vs. type 2 diabetes, Fig. 1).”
- Also stated in: § Statistical analysis · plain
“Low TT (Ͻ10 nmol/liter) (%) 7% 43% 42%”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Abstract
plainn = 69- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Prevalence of testosterone deficiency in men with type 1 diabetes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“57% had a reduced calculated free testosterone”
- Also stated in: § Discussion · plain
“57% had low cFT levels”
- Also stated in: § Statistical analysis · plain
“Low cFT (Ͻ0.23 nmol/liter) (%) 20% 57% 60%”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Abstract
plainn = 580- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After adjusting for age, body mass index (BMI), and other confounding factors, the frequency of low TT levels remained significantly higher in men with type 2 diabetes when compared with those with type 1 diabetes (adjusted odds ratio ϭ 4.0; 95% CI ϭ 1.5-10.7;P ϭ 0.005).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 1 diabetes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For each decade of life, the prevalence of low cFT levels effectively doubled (adjusted odds ratio for low cFT levels ϭ 2.4; 95% CI ϭ 1.4 -3.9).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 1 diabetes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This frequency of low TT levels in men with type 1 diabetes was not significantly greater than observed in reproductively normal young men (21).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 1 diabetes
What the sources say
- Not checked yetcites [21] Sikaris, 2005, Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays., J Clin Endocrinol Metab source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in men with type 2 diabetes, the major predictor of cFT levels in individuals with type 1 diabetes was age (Fig. 2B).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 1 diabetes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, when SHBG was included in the model, this difference between type 1 and type 2 diabetes was eliminated (P ϭ 0.16).”
- Also stated in: § Discussion · plain
“When SHBG was included into the model, this difference between type 1 and type 2 diabetes was eliminated (P ϭ 0.16).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 1 diabetes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“20.3% of men with type 1 diabetes had low calculated free testosterone”
- Also stated in: § Prevalence of testosterone deficiency in men with type 1 diabetes · plain
“one in five men with type 1 diabetes had low cFT levels (20.3%, Fig. 1)”
- Also stated in: § Statistical analysis · plain
“Low cFT (Ͻ0.23 nmol/liter) (%) 20% 57% 60%”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Abstract
plainn = 69- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Prevalence of testosterone deficiency in men with type 1 diabetes · plain
In the paper
“insulin resistance (as estimated by the HOMA-IR equation) (23) was independently associated with low TT levels (odds ratio ϭ 1.2; 95% CI ϭ 1.0 -1.4), after adjusting for age, BMI, treatment regimens, and other potentially confounding variables.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Testosterone indices and insulin resistance
What the sources say
- Not checked yetcites [23] Wallace, 2004, Use and abuse of HOMA modeling., Diabetes Care source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The inverse association between cFT levels and age (Fig. 2B) was significantly stronger that that observed for TT (P Ͻ 0.01)”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 2 diabetes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 10
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“finding that 27 and 33% of individuals with low TT and cFT levels respectively had levels in the normal range when retested.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the second analysis, the prevalence of testosterone deficiency defined by low TT levels (Ͻ10 nmol/liter) was not significantly different from obtained at the first estimation (39 vs. 42%, P ϭ 0.2), and there was a strong correlation between estimations (r 2 ϭ 0.73, Fig. 3A).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Changes in testosterone levels over time
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas the utility of testosterone replacement remains to be established in prospective trials.”
- Also stated in: § Discussion · hedged
“Although there is a strong rationale for testosterone replacement, the balance of benefits and risks is currently unknown and still to be defined by large and long-term clinical trials.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § Discussion · hedged
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“possibly because of the age-associated rise in SHBG (Fig. 2C).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Prevalence of testosterone deficiency in men with type 2 diabetes
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“None of these men received testosterone therapy.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Changes in testosterone levels over time
plainn = 262- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Interpretation of our study is therefore limited because we did not obtain a detailed record of symptomatology history.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All men gave written informed consent, and the study was approved by the Human Research Ethics Committee, Research Ethics Unit, Austin Health.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Cross-sectional survey
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“However, testosterone may have deleterious actions on prostate disease, sleep apnea, and possibly cardiovascular risk (35).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
What the sources say
- Not checked yetcites [35] Rhoden, 2004, Risks of testosterone-replacement therapy and recommendations for monitoring., N Engl J Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consequently, the appropriate clinical response to this emerging problem remains to be determined.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
In the paper
“previous studies have reported an association of loss of weight in obese insulinresistant men with increased testosterone levels (30).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
What the sources say
- Not checked yetcites [30] Niskanen, 2004, Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome., Diabetes Obes Metab source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Certainly, testosterone replacement can improve performance, mood, and libido in men with hypogonadism (22) and augments insulin sensitivity (11,15).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
What the sources say
- Not checked yetcites [22] Bhasin, 2006, Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline., J Clin Endocrinol Metab [Erratum (2006) 91:1995–2010] source
- Not checked yetcites [11] Kapoor, 2006, Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes., Eur J Endocrinol source
- Not checked yetcites [15] Simon, 2001, Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial., Diabetes Care source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The strengths of this study include the large number subjects, inclusion of a large cohort of patients with type 1 diabetes, measurement of serum testosterone levels at the appropriate time of day (early morning), accurate assays for total and free testosterone levels, and longitudinal follow-up in a substantial number of men with type 2 diabetes.”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Indeed, reduced SHBG has been suggested as a surrogate marker for insulin resistance (33).”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Discussion
What the sources say
- Not checked yetcites [33] Jayagopal, 2003, The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance., J Clin Endocrinol Metab source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The cohort of men attending a single tertiary referral clinic is representative of men with diabetes generally.
“in a large, unselected cohort of men with type 1 or type 2 diabetes presenting at a single center”
“large unselected cohort of men presenting to a single tertiary referral center”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In fact, multiple studies confirmed the association between low or inappropriate T levels in men and T2D and obesity [167–170].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [168]
In the citing paper
“A longitudinal study in 265 men with a baseline hemoglobin A1c of 7.6% reported an inverse relationship between changes in glycemic control and testosterone levels.”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [35]
In the citing paper
“In those whose glycemic control improved over time, testosterone increased, whereas in those whose control worsened, testosterone decreased (35).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [35]
In the citing paper
“Approximately, 50% of older (age >40 years) male patients with type 2 diabetes mellitus (DM2) have decreased testosterone (T) levels”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Testosterone indices and insulin resistance
“higher hs-CRP levels (median 7.7 vs. 4.5, P Ͻ 0.01)”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Statistical analysis
“hs-CRP (IU/ml) 1.5 (0.2-11.5) 3.0 (0.2-192) 2.9 (0.2-58)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Cohort characteristics
“One third of men with type 2 diabetes had documented macrovascular disease”
§ Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes > Statistical analysis
“Macrovascular disease (%) 16% 42% 40%”
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Androgens and Cardiovascular Disease
Liu, P. Y., Death, A. K., & Handelsman, D. J. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0005 · Cited by 695
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693
Can clinical factors estimate insulin resistance in type 1 diabetes?
Williams, K. V., Erbey, J. R., Becker, D., Arslanian, S., & Orchard, T. J. (2000) · Diabetes · doi:10.2337/diabetes.49.4.626 · Cited by 640
Cited by
Sorted by citations
Skakkebæk, N. E., Meyts, E. R., Louis, G. M. B., Toppari, J., Andersson, A., Eisenberg, M. L., Jensen, T. K., Jørgensen, N., Swan, S. H., Sapra, K. J., et al. (2015) · Physiological Reviews · doi:10.1152/physrev.00017.2015 · Cited by 1,030
Physical activity and exercise: Strategies to manage frailty
Angulo, J., El Assar, M., Álvarez-Bustos, A., & Rodríguez-Mañas, L. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101513 · Cited by 771
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Klinefelter Syndrome—A Clinical Update
Groth, K. A., Skakkebaek, A. H., Høst, C., Gravholt, C. H., & Bojesen, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2382 · Cited by 513
Nehra, A. X., Jackson, G., Miner, M. M., Billups, K. L., Burnett, A. L. “., Buvat, J., Carson, C. C., Cunningham, G. R., Ganz, P., Goldstein, I., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.06.015 · Cited by 475
Testosterone concentrations in diabetic and nondiabetic obese men
Dhindsa, S., Miller, M. G., McWhirter, C. L., Mager, D. E., Ghanim, H., Chaudhuri, A., & Dandona, P. (2010) · Diabetes Care · doi:10.2337/dc09-1649 · Cited by 352
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
Grossmann, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0118 · Cited by 350
Self-citationUpdate: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity
Dandona, P., & Dhindsa, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2724 · Cited by 313
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D., & LeRoith, D. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0374 · Cited by 308
Diabetes-induced hyperglycemia impairs male reproductive function: A systematic review
Maresch, C. C., Stute, D. C., Alves, M. G., Oliveira, P. F., de Kretser, D. M., & Linn, T. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx033 · Cited by 294
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
Rao, P. M., Kelly, D. M., & Jones, T. H. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.122 · Cited by 292
The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance
Traish, A. M., Saad, F., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005751 · Cited by 266
Grossmann, M., & Matsumoto, A. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3580 · Cited by 246
Self-citationHamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J. M., Joon, D. L., Bolton, D. M., Zajac, J. D., & Grossmann, M. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03942.x · Cited by 198
Self-citationThe effects of oestrogens and their receptors on cardiometabolic health
Morselli, E., Santos, R. D. S., Criollo, A., Nelson, M. D., Palmer, B. F., & Clegg, D. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.12 · Cited by 195
Alzheimer’s Disease and Type 2 Diabetes: Multiple Mechanisms Contribute to Interactions
Jayaraman, A., & Pike, C. J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0476-2 · Cited by 185
Angulo, J., Assar, M. E., & Rodríguez‐Mañas, L. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.06.001 · Cited by 195
Santos-Marcos, J. A., Mora-Ortiz, M., Tena‐Sempere, M., López‐Miranda, J., & Camargo, A. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00490-2 · Cited by 202
Noto, H., Tsujimoto, T., Sasazuki, T., & Noda, M. (2011) · Endocrine Practice · doi:10.4158/ep10357.ra · Cited by 169
Gianatti, E., Dupuis, P., Hoermann, R., Strauss, B. J., Wentworth, J. M., Zajac, J. D., & Grossmann, M. (2014) · Diabetes Care · doi:10.2337/dc13-2845 · Cited by 168
Self-citationLongitudinal changes in testosterone over five years in community-dwelling men
Shi, Z., Araujo, A. B., Martin, S., O'Loughlin, P., & Wittert, G. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3842 · Cited by 165
Dhindsa, S., Zhang, N., McPhaul, M. J., Wu, Z. R., Ghoshal, A. K., Erlich, E. C., Mani, K. M., Randolph, G. J., Edwards, J. R., Mudd, P. A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.11398 · Cited by 167
Hypogonadism and male obesity: Focus on unresolved questions
Grossmann, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13723 · Cited by 164
Self-citationTestosterone in men with advanced liver disease: Abnormalities and implications
Sinclair, M. J., Grossmann, M., Gow, P. J., & Angus, P. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12695 · Cited by 163
Self-citationPrediabetes and associated disorders
Buysschaert, M., Medina, J. L., Bergman, M., Shah, A., & Lonier, J. (2014) · Endocrine · doi:10.1007/s12020-014-0436-2 · Cited by 164
Hypogonadotropic Hypogonadism in Men With Diabesity
Dhindsa, S., Ghanim, H., Batra, M., & Dandona, P. (2018) · Diabetes Care · doi:10.2337/dc17-2510 · Cited by 162
Saboor Aftab, S. A., Kumar, S., & Barber, T. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12092 · Cited by 157
The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process
Jones, T. H., & Saad, F. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.04.016 · Cited by 153
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0124 · Cited by 162
Metabolic Disorders and Male Hypogonadotropic Hypogonadism
Pivonello, R., Menafra, D., Riccio, E., Garifalos, F., Mazzella, M., de Angelis, C., & Colao, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00345 · Cited by 149
Grossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12664 · Cited by 139
Self-citationThe Roles of Androgens in Humans: Biology, Metabolic Regulation and Health
Alemany, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911952 · Cited by 150
Yeap, B. B., Chubb, S. A. P., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., & Norman, P. E. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0348 · Cited by 128
Low Estradiol Concentrations in Men With Subnormal Testosterone Concentrations and Type 2 Diabetes
Dhindsa, S., Furlanetto, R. W., Vora, M., Ghanim, H., Chaudhuri, A., & Dandona, P. (2011) · Diabetes Care · doi:10.2337/dc11-0208 · Cited by 127
Gannon, O. J., Robison, L. S., Salinero, A. E., Abi-Ghanem, C., Mansour, F. M., Kelly, R. D., Tyagi, A., Brawley, R. R., Ogg, J. D., & Zuloaga, K. L. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02466-2 · Cited by 127
Substantially increased risk of cancer in patients with diabetes mellitus
Noto, H., Osame, K., Sasazuki, T., & Noda, M. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2010.06.004 · Cited by 126
Maric, C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90505.2008 · Cited by 124
Naghii, M. R., Mofid, M., Asgari, A. R., Hedayati, M., & DANESHPOUR, M. S. (2010) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2010.10.001 · Cited by 125
Groti, K., Žuran, I., Antonič, B., Foršnarič, L., & Pfeifer, M. (2018) · The Aging Male · doi:10.1080/13685538.2018.1468429 · Cited by 117
Caronia, L. M., Dwyer, A. A., Hayden, D., Amati, F., Pitteloud, N., & Hayes, F. J. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04486.x · Cited by 117
Testosterone and ill-health in aging men
Yeap, B. B. (2009) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1050 · Cited by 112
Giagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
Testosterone and type 2 diabetes
Grossmann, M., Gianatti, E. J., & Zajac, J. D. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833919cf · Cited by 108
Self-citationGrossmann, M., Hamilton, E. J., Gilfillan, C. P., Bolton, D. M., Joon, D. L., & Zajac, J. D. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb02979.x · Cited by 106
Self-citationThe role of hypogonadism in Klinefelter Syndrome
Bojesen, A., Høst, C., Skakkebaek, A. H., & Groth, K. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122201 · Cited by 109
Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis
Yao, Q., Wang, B., An, X., Zhang, J., & Ding, L. (2017) · Endocrine Connections · doi:10.1530/ec-17-0253 · Cited by 100
Testosterone and glucose metabolism in men: current concepts and controversies
Grossmann, M. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0393 · Cited by 104
Self-citationNarinx, N., David, K., Walravens, J., Vermeersch, P., Claessens, F., Fiers, T., Lapauw, B., Antonio, L., & Vanderschueren, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04562-1 · Cited by 96
Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study
Al Hayek, A., Khader, Y., Jafal, S., Khawaja, N., Robert, A., & Ajlouni, K. (2013) · Journal of Family and Community Medicine · doi:10.4103/2230-8229.122006 · Cited by 94
Low testosterone levels as an independent predictor of mortality in men with chronic liver disease
Grossmann, M., Hoermann, R., Gani, L. U., Chan, I., Cheung, A. S., Gow, P. J., Li, A., Zajac, J. D., & Angus, P. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04347.x · Cited by 92
Self-citationType 2 Diabetes and Cancer: What Is the Connection?
Cannata, D., Fierz, Y., Vijayakumar, A., & LeRoith, D. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20167 · Cited by 94
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 90
Sexual dysfunction in men with type 2 diabetes
Isidro, M. L. (2012) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2011-130069 · Cited by 86
Androgens and cardiovascular disease
Yeap, B. B. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283383031 · Cited by 87
Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment
Gianatti, E., & Grossmann, M. (2019) · Diabetic Medicine · doi:10.1111/dme.13977 · Cited by 86
Self-citationTestosterone and the aging male: To treat or not to treat?
Bain, J. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.009 · Cited by 84
Human androgen deficiency: insights gained from androgen receptor knockout mouse models
Zajac, J. D., Rana, K., & Davey, R. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122590 · Cited by 91
Self-citationTestosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer
Loeb, S., Folkvaljon, Y., Damber, J., Alukal, J. P., Lambe, M. P., & Stattin, P. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5304 · Cited by 84
Bertram, S., Brixius, K., & Brinkmann, C. K. (2016) · Endocrine · doi:10.1007/s12020-016-0976-8 · Cited by 89
The prevalence of and risk factors for androgen deficiency in aging Taiwanese men
Liu, C.-C., Wu, W.-J., Lee, Y.-C., Wang, C.-J., Ke, H.-L., Li, W.-M., Hsiao, H.-L., Yeh, H.-C., Li, C.-C., Chou, Y.-H., et al. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01171.x · Cited by 82
Sex hormones, obesity and type 2 diabetes: is there a link?
Gambineri, A., & Pelusi, C. (2018) · Endocrine Connections · doi:10.1530/ec-18-0450 · Cited by 82
Šimonienė, D., Platūkienė, A., Prakapienė, E., Radzevičienė, L., & Veličkienė, D. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00729-5 · Cited by 83
Cai, H., Xu, Z., Xu, T., Yu, B., & Zou, Q. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2582 · Cited by 80
Testosterone concentrations in young pubertal and post-pubertal obese males
Mogri, M., Dhindsa, S., Quattrin, T., Ghanim, H., & Dandona, P. (2013) · Clinical Endocrinology · doi:10.1111/cen.12018 · Cited by 79
Rana, K., Fam, B. C., Clarke, M. V., Pang, T. P. S., Zajac, J. D., & MacLean, H. E. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00584.2010 · Cited by 78
Self-citationInder, W. J., Jang, C., Obeyesekere, V. R., & ALFORD, F. P. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03683.x · Cited by 78
Diet-induced obesity and low testosterone increase neuroinflammation and impair neural function
Jayaraman, A., Lent-Schochet, D., & Pike, C. J. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0162-y · Cited by 81
Obesity, type 2 diabetes, and testosterone in ageing men
Wittert, G., & Grossmann, M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09746-5 · Cited by 89
Self-citationAndrogens, diabetes and prostate cancer
Grossmann, M., & Wittert, G. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0067 · Cited by 78
Self-citationPiani, F., Melena, I. L., Tommerdahl, K. L., Nokoff, N., Nelson, R. G., Pavkov, M. E., van Raalte, D. H., Cherney, D. Z. I., Johnson, R. J., Nadeau, K. J., et al. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107841 · Cited by 78
The practical management of testosterone deficiency in men
Aversa, A., & Morgentaler, A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.238 · Cited by 75
Are declining testosterone levels a major risk factor for ill-health in aging men?
Yeap, B. B. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.60 · Cited by 75
Androgenetic alopecia and insulin resistance in young men
González‐González, J. G., Mancillas‐Adame, L. G., Fernández‐Reyes, M., Gómez‐Flores, M., Lavalle-Gonzalez, F. J., Ocampo‐Candiani, J., & Villarreal‐Pérez, J. Z. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03508.x · Cited by 73
Maric, C., Forsblom, C. M., Thorn, L. M., Wadén, J., & Groop, P. (2010) · Steroids · doi:10.1016/j.steroids.2010.01.011 · Cited by 72
Type 2 diabetes mellitus, glycemic control, and cancer risk
Onitilo, A. A., Stankowski, R. V., Berg, R. L., Engel, J. M., Glurich, I., Williams, G. M., & Doi, S. A. R. (2013) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e3283656394 · Cited by 72
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Self-citationGrossmann, M., & Zajac, J. D. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03939.x · Cited by 72
Self-citationGianatti, E. J., Dupuis, P., Hoermann, R., Zajac, J. D., & Grossmann, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1872 · Cited by 67
Self-citationDeterminants of sexual dysfunction among clinically diagnosed diabetic patients
Owiredu, W. K., Amidu, N., Alidu, H. W., Sarpong, C., & Gyasi-Sarpong, C. K. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-70 · Cited by 68
Sex Differences in Diabetic Kidney Disease
Maric‐Bilkan, C. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.026 · Cited by 78
Noto, H., Tsujimoto, T., & Noda, M. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00183.x · Cited by 63
Magnussen, L. V., Glintborg, D., Hermann, A. P., HOUGAARD, D. M., Højlund, K., & Andersen, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12701 · Cited by 64
Pozzo, M. J., Mociulsky, J., Martinez, E. T., Senatore, G., Farias, J. M., Sapetti, A., Sanzana, M. G., Gonzalez, P., Cafferata, A., Peloche, A., et al. (2014) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000433949.24277.19 · Cited by 64
Hematological changes during androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.102 · Cited by 62
Self-citationTestosterone meets albumin – the molecular mechanism of sex hormone transport by serum albumins
Czub, M. P., Venkataramany, B. S., Majorek, K. A., Handing, K. B., Porebski, P. J., Beeram, S. R., Suh, K., Woolfork, A. G., Hage, D. S., Shabalin, I. G., et al. (2019) · Chemical Science · doi:10.1039/c8sc04397c · Cited by 61
Low testosterone and anaemia in men with type 2 diabetes
Grossmann, M., Panagiotopolous, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., Jerums, G., & Thomas, M. C. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03357.x · Cited by 60
Self-citationWon, E.-Y., Yoon, M., Kim, S. W., Jung, Y., Bae, H.-W., Lee, D., Park, S. G., Lee, C., Hwang, G., & Chi, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075998 · Cited by 62
Sinclair, M. J., Grossmann, M., Angus, P., Hoermann, R., Hey, P., Scodellaro, T., & Gow, P. J. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13182 · Cited by 63
Self-citationHolt, S. K., Lopushnyan, N. A., Hotaling, J. M., Sarma, A. V., Dunn, R. L., Cleary, P. A., Braffett, B. H., Gatcomb, P., Martin, C. L., Herman, W. H., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1317 · Cited by 57
Anderson, R. L., Ternes, S. B., Strand, K. A., & Rowling, M. J. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00218.2010 · Cited by 56
Jackson, G., Nehra, A. X., Miner, M. M., Billups, K. L., Burnett, A. L. “., Buvat, J., Carson, C. C., Cunningham, G. R., Goldstein, I., Guay, A. T., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12200 · Cited by 54
Do low testosterone levels contribute to ill-health during male ageing?
Yeap, B. B., de Araújo, A. B., & Wittert, G. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2012.725461 · Cited by 53
Farias, J. M., Tinetti, M., Khoury, M. C., & Umpierrez, G. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2585 · Cited by 51
Adverse health effects of testosterone deficiency (TD) in men
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.010 · Cited by 51
Nuclear receptors in the kidney during health and disease
Libby, A. E., Jones, B. A., Santiago, I. L., Rowland, E., & Levi, M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100935 · Cited by 49
RAS and sex differences in diabetic nephropathy
Clotet, S., Riera, M., Pascual, J., & Soler, M. J. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00292.2015 · Cited by 49
Dhindsa, S., Ghanim, H., Batra, M., Kuhadiya, N. D., Abuaysheh, S., Green, K., Makdissi, A., Chaudhuri, A., & Dandona, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13130 · Cited by 49
Traish, A. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_22 · Cited by 50
Bakhtyukov, A. A., Derkach, K. V., Sorokoumov, V. N., Stepochkina, A. M., Romanova, I. V., Morina, I. Y., Zakharova, I. O., Bayunova, L. V., & Shpakov, A. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010198 · Cited by 50
Hypogonadotropic Hypogonadism in Men with Type 2 Diabetes
Dandona, P., Dhindsa, S., Chandel, A., & Chaudhuri, A. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2001 · Cited by 47
Metadata
- Authors
- Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G.
- Affiliations
- The University of Melbourne (AU)
- Baker Heart and Diabetes Institute (AU)
- Corresponding author
- Grossmann, Mathis
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1834-1840
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1975633687
- Semantic Scholar
- 02f5d7f00e960755b4687b5424387d4da02771b3
- Cited by
- 468
- References
- 37
- Citations by year
- 2026: 22 · 2025: 22 · 2024: 22 · 2023: 23 · 2022: 28 · 2021: 24 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 33 · 2016: 34 · 2015: 30 · 2014: 41 · 2013: 31 · 2012: 30
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Keywords
- androgen deficiency, insulin resistance, type 2 diabetes, type 1 diabetes, men, free testosterone, total testosterone, testosterone replacement therapy, prevalence
- MeSH terms
- Adult, Aged, Cross-Sectional Studies, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Male, Middle Aged, Sex Hormone-Binding Globulin, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
